Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on the effectiveness of the combination of pembrolizumab, trastuzumab, capecitabine and oxaliplatin in HER2+ metastatic esophagogastric adenocarcinoma (mEGA)

Tags: ASCO GI Conference CoverageEsophageal

Published: 04 February 2019

Recent Videos: ASCO GI Conference Coverage

video

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, outlines the role ...

video

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about reliable ...

video

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, offers opinion on ...

video

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, considers the role of ...

video

John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer

Dr. Strickler, MD, Assistant Professor of Medicine, Duke Cancer Institute, considers the good news and the bad news regarding molecular ...

video

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, offers his opinion on how next-generation sequencing (NGS) fits into diagnosis ...

video

John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer

Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, offers his impressions of the study presented at the 2019 Gastrointestinal ...

Related Videos

video-image

Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC

video-image

David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer

video-image

Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC

video-image

David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms

video-image

John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer

video-image

John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC

video-image

John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer

video-image

John Strickler, MD, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mEGA

video-image

Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma

video-image

Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC

video-image

Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019

video-image

Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC

video-image

Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer

video-image

Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC

video-image

Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer

video-image

Raymond Wadlow, MD, on the outcomes of Keynote 181 in esophageal cancer

video-image

Bassel El-Reyes, MD, speculates on promising novel therapies being developed for pancreatic cancer

video-image

Bassel El-Reyes, MD, considers upfront surgery for resectable pancreatic cancer

video-image

Martine Extermann, MD, PhD, on identifying the right treatment for patients with gastric cancer

video-image

Bassel El-Reyes, MD, offers his opinion on NGS & BRCA gene testing for pancreatic cancer

video-image

Martine Extermann, MD, PhD, shares the results of the FOLFOX +/- andecaliximab study from GI '19

video-image

Bassel El-Reyes, MD, regarding molecular subtyping of pancreatic cancer

video-image

Martine Extermann, MD, PhD, on the investigation of TAS-102 in metastatic gastric cancer

video-image

Bassel El-Reyes, MD, on screening patients at high risk for pancreatic cancer

video-image

Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer

video-image

David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer

video-image

Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC

video-image

David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019

video-image

Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer

video-image

Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer

video-image

Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma

video-image

Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma

video-image

Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment

video-image

Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma

video-image

Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma

video-image

Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma

video-image

Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC

video-image

Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC

video-image

Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC

video-image

Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019

video-image

Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers

video-image

Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC

video-image

Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC

video-image

Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC

video-image

Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC

video-image

Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)

video-image

Alan Venook, MD, discusses next generation sequencing and mCRC treatment

video-image

Axel Grothey, MD, elaborates on next generation sequencing and mCRC

video-image

Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer

video-image

Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer

video-image

Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC

video-image

Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer

video-image

Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC

video-image

Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer

video-image

Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)

video-image

Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer

video-image

Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC

video-image

Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC

video-image

Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC

video-image

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

video-image

Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions

video-image

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

video-image

Howard Hochster, MD, on the management of mCRC patients receiving regorafenib

video-image

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

video-image

Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients

video-image

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

video-image

Howard Hochster, MD, regarding the role of genetic testing in mCRC